[go: up one dir, main page]

MXPA03003032A - Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. - Google Patents

Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.

Info

Publication number
MXPA03003032A
MXPA03003032A MXPA03003032A MXPA03003032A MXPA03003032A MX PA03003032 A MXPA03003032 A MX PA03003032A MX PA03003032 A MXPA03003032 A MX PA03003032A MX PA03003032 A MXPA03003032 A MX PA03003032A MX PA03003032 A MXPA03003032 A MX PA03003032A
Authority
MX
Mexico
Prior art keywords
estrogen
treatment
combination therapy
sensitive disease
disease
Prior art date
Application number
MXPA03003032A
Other languages
English (en)
Inventor
S Mark Moran
Original Assignee
Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedicines Inc filed Critical Biomedicines Inc
Publication of MXPA03003032A publication Critical patent/MXPA03003032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA03003032A 2000-10-06 2001-10-03 Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. MXPA03003032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23877200P 2000-10-06 2000-10-06
PCT/US2001/031060 WO2002030429A1 (en) 2000-10-06 2001-10-03 Combination therapy for the treatment of estrogen-sensitive disease

Publications (1)

Publication Number Publication Date
MXPA03003032A true MXPA03003032A (es) 2003-06-06

Family

ID=22899242

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003032A MXPA03003032A (es) 2000-10-06 2001-10-03 Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.

Country Status (14)

Country Link
US (5) US20020119502A1 (es)
EP (1) EP1330251A4 (es)
JP (1) JP2004510994A (es)
CN (1) CN1471400A (es)
AU (1) AU2001296578A1 (es)
BR (1) BR0114655A (es)
CA (1) CA2424299A1 (es)
HU (1) HUP0301276A2 (es)
IL (1) IL155237A0 (es)
MX (1) MXPA03003032A (es)
NZ (1) NZ525105A (es)
PL (1) PL361874A1 (es)
RU (1) RU2003112974A (es)
WO (1) WO2002030429A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219617T2 (de) * 2001-05-16 2008-01-03 Novartis Ag Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
WO2011002096A1 (ja) * 2009-07-03 2011-01-06 独立行政法人理化学研究所 Ｐｅｔ用標識化合物
PH12012502419A1 (en) 2010-06-10 2022-03-21 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
WO2017093776A1 (en) * 2015-11-30 2017-06-08 Pharnext Method for adapting doses of combination therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US5064813A (en) * 1984-08-02 1991-11-12 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US5023234A (en) * 1985-02-08 1991-06-11 Fernand Labrie Combination male breast cancer therapy
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
NZ244499A (en) * 1989-03-10 1999-05-28 Endorecherche Inc Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites

Also Published As

Publication number Publication date
JP2004510994A (ja) 2004-04-08
IL155237A0 (en) 2003-11-23
RU2003112974A (ru) 2004-11-27
US20020119502A1 (en) 2002-08-29
AU2001296578A1 (en) 2002-04-22
US20050130945A1 (en) 2005-06-16
HUP0301276A2 (hu) 2003-11-28
US20050228053A1 (en) 2005-10-13
PL361874A1 (en) 2004-10-04
US20050176691A1 (en) 2005-08-11
BR0114655A (pt) 2004-02-10
EP1330251A1 (en) 2003-07-30
NZ525105A (en) 2004-10-29
EP1330251A4 (en) 2006-03-15
CN1471400A (zh) 2004-01-28
WO2002030429A1 (en) 2002-04-18
CA2424299A1 (en) 2002-04-18
US20050232862A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL196301A0 (en) Medicament for the treatment of hapatitis c
MXPA03001419A (es) Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
AP2003002842A0 (en) Phenethanolamine derivatives for treatment of respiratory disease.
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB0001710D0 (en) Therapeutic treatment
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
IL142581A (en) Medicament for treating heart disease
AU2096002A (en) Therapeutic treatment
GB0029524D0 (en) Disease treatment
GB0128628D0 (en) Disease treatment
HK1056828A1 (en) Treatment of burns.
AP2004003014A0 (en) Use of specific dose of fondaparinux sodium for the treatment of ACS.
GB2397018B (en) Combination therapy for treating disease
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
ZA200304439B (en) Therapeutic treatment.